Skip to main content
. 2019 Aug 7;22:132–141. doi: 10.1016/j.jot.2019.07.003

Figure 1.

Figure 1

AP enhanced the sensitivity of osteosarcoma cells to DOX. (A and B) Cell viability of KHOS and U2OS cells treated with AP (2μM for both KHOS and U2OS), DOX (50 nM for KHOS, 25 nM for U2OS), or AP+DOX were evaluated by MTT assay at 24 h, 48 h, and 72 h. (C and D) Colony formation assay of KHOS and U2OS cells treated with AP, DOX, or both drugs in combination for 7 days. (E and F) After treating with DMSO, AP, DOX, or AP+DOX, KHOS and U2OS cells were subjected to cell apoptosis analysis using flow cytometry. Data are represented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. AP = apatinib; DOX = doxorubicin; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; DMSO = dimethyl sulfoxide; PE = phycoerythrin; FITC = fluorescein isothiocyanate; SD = standard deviation.